Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) for reimbursement as a treatment option for the maintenance treatment (84 day) of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.

This is written in the approval document as:

Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.

Citation

RiTUXimab 375 mg/m2 Maintenance Therapy-84 day, 2025, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6640/540_v2a_riTUXimab_375_mgm2_Therapy_84_day.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) CD20 + Non-Hodgkin Lymphoma Rituximab
HSE (1) CD20 + Follicular Lymphoma Rituximab